Related Experiment Video
Updated: May 20, 2026
12:24
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
CD20 gene deletion causes a CD20-negative relapse in diffuse large B-cell lymphoma
Tsuyoshi Nakamaki1, Kunihiko Fukuchi, Hidetoshi Nakashima
1Division of Hematology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan. nakamaki@med.showa-u.ac.jp
European Journal of Haematology
|July 19, 2012
Summary
CD20-negative relapse in diffuse large B-cell lymphoma (DLBCL) is linked to poor outcomes. This study identifies CD20 gene deletion as a key mechanism causing this relapse, impacting therapeutic targets.
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Background:
- CD20-negative relapse in diffuse large B-cell lymphoma (DLBCL) presents significant clinical challenges, often correlating with chemo-refractory disease.
- Loss of CD20 expression limits the efficacy of rituximab-based immunotherapies.
Observation:
- A novel DLBCL cell line (SD07) was established from a patient experiencing CD20-negative relapse after extensive immunochemotherapy, including rituximab.
- The SD07 cell line exhibited identical immunoglobulin kappa rearrangement to the patient's relapsed lymphoma cells, confirming its origin.
Findings:
- SD07 cells demonstrated a homozygous deletion of the CD20 gene, associated with a loss of the 11q12 copy number.
- This is the first documented case definitively proving that CD20 gene deletion is the molecular cause of CD20-negative relapse in a subset of DLBCL.
Implications:
- CD20 gene deletion represents a key molecular mechanism contributing to CD20-negative relapse in specific DLBCL cases.
- Understanding this mechanism is crucial for developing alternative therapeutic strategies for patients with chemo-refractory, CD20-negative DLBCL.
